NVNO
enVVeno Medical Corporation
$0.80
-$0.07(-8.14%)
54
Overall
60
Value
75
Tech
28
Quality
Market Cap
$17.20M
Volume
2.08M
52W Range
$0.77 - $5.70
Target Price
$12.50
Order:
Income Statement
| Metric | Trend | Chart | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||
| Total Revenue | $186.6K | $31.2K | -- | -- | -- | -- | -- | ||
| Total Revenue | $186.6K | $31.2K | -- | -- | -- | -- | -- | ||
| GROSS PROFIT | |||||||||
| Gross Profit | $186.6K | $31.2K | -- | -- | -- | -- | -- | ||
| OPERATING EXPENSES | |||||||||
| Operating Expenses | $14.3M | $7.1M | $9.1M | $16.9M | $24.9M | $25.2M | $23.8M | ||
| Research & Development | $1.2M | $2.2M | $4.3M | $5.7M | $9.9M | $13.6M | $12.2M | ||
| Research Expense | $1.2M | $2.2M | $4.3M | $5.7M | $9.9M | $13.6M | $12.2M | ||
| Selling, General & Administrative | $6.5M | $4.9M | $4.9M | $11.2M | $15.0M | $11.7M | $11.6M | ||
| Selling & Marketing Expenses | $6.5M | $4.9M | -- | -- | -- | -- | -- | ||
| General & Administrative Expenses | $-348.2K | -- | $4.9M | $11.2M | $15.0M | $11.7M | $11.6M | ||
| Salaries & Wages | $-1.9M | $-942.0K | $881.2K | $-6.0M | $9.0M | $5.2M | $4.1M | ||
| Depreciation & Amortization | $6.6M | $-46.0K | $100.0K | $100.0K | $200.0K | $200.0K | $200.0K | ||
| Depreciation & Amortization | $6.6M | $-46.0K | $100.0K | $100.0K | $200.0K | $200.0K | $200.0K | ||
| Amortization | $6.6M | $-77.6K | -- | -- | -- | -- | -- | ||
| Other Operating Expenses | -- | $-342.0K | $342.0K | $345.9K | $389.0K | $389.0K | $389.0K | ||
| OPERATING INCOME | |||||||||
| Operating income | $-14.1M | $-7.1M | $-9.1M | $-16.9M | $-24.9M | $-25.2M | $-23.8M | ||
| EBITDA | $-5.4M | $-7.3M | $-8.8M | $-16.4M | $-24.4M | $-27.1M | $-25.3M | ||
| NON-OPERATING ITEMS | |||||||||
| Interest Expense (Non-Operating) | $298.2K | $49.9K | $-3.7K | $-19.0K | $-161.0K | -- | -- | ||
| Intinc | -- | -- | -- | -- | $161.0K | $180.0K | $389.0K | ||
| Net Non-Operating Interest Income/Expense | $-298.2K | $-49.9K | $3.7K | $19.0K | $161.0K | $180.0K | $389.0K | ||
| Gain on Sale of Securities | -- | -- | $211.8K | -- | $102.0K | $1.1M | $1.6M | ||
| Other Income/Expense | $-1.7M | -- | $4.1K | $-346.0K | $102.0K | $-1.5M | $-1.6M | ||
| Other Special Charges | $1.5M | -- | $-215.9K | $346.0K | $-53.0K | $1.7M | $2.0M | ||
| SPECIAL ITEMS | |||||||||
| Special Income Charges | $-319.6K | $-588.8K | -- | -- | -- | -- | -- | ||
| Impairment of Capital Assets | $319.6K | $588.8K | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | |||||||||
| EBIT | $-12.1M | $-7.7M | $-9.1M | $-16.9M | $-24.9M | $-27.7M | $-25.8M | ||
| Pre-Tax Income | $-12.4M | $-7.7M | $-9.1M | $-16.5M | $-24.7M | $-23.5M | $-21.8M | ||
| INCOME TAX | |||||||||
| Tax Provision | -- | -- | $-1.8M | $-2.7M | $-3.8M | $-4.2M | $-4.0M | ||
| NET INCOME | |||||||||
| Net Income | $-12.4M | $-7.7M | $-9.1M | $-16.5M | $-24.7M | $-23.5M | $-21.8M | ||
| Net Income (Continuing Operations) | $-12.4M | $-7.7M | $-9.1M | $-16.5M | $-24.7M | $-23.5M | $-21.8M | ||
| Net Income (Discontinued Operations) | $-12.4M | $-7.7M | $-9.1M | $-16.5M | $-24.7M | $-23.5M | $-21.8M | ||
| Net Income (Common Stockholders) | $-15.8M | $-7.7M | $-9.7M | $-16.5M | $-24.7M | $-23.5M | $-21.8M | ||
| Normalized Income | -- | -- | -- | $-19.2M | $-28.4M | -- | $-25.8M | ||
| TOTALS | |||||||||
| Total Expenses | $14.3M | $7.1M | $9.1M | $16.9M | $24.9M | $25.2M | $23.8M | ||
| SHARE & EPS DATA | |||||||||
| Average Shares Outstanding | $374.5K | $630.4K | $1.3M | $8.7M | $11.2M | $12.3M | $17.1M | ||
| Average Shares Outstanding (Diluted) | $283.5K | $630.4K | $1.3M | $8.7M | $11.2M | $12.3M | $17.1M | ||
| Shares Outstanding | $566.7K | $769.3K | $8.5M | $9.5M | $9.5M | $19.2M | $17.5M | ||
| Basic EPS | -- | -- | $-7.54 | $-1.9 | $-2.2 | $-1.91 | $-1.27 | ||
| Basic EPS (Continuing Operations) | -- | -- | $-7.54 | $-1.9 | $-2.2 | $-1.91 | $-1.27 | ||
| Diluted EPS | $-43.75 | $-12 | $-7.54 | $-1.9 | $-2.2 | $-1.91 | $-1.27 | ||
| Diluted EPS (Continuing Operations) | -- | $-12 | -- | -- | -- | $-1.91 | $-1.27 | ||
| OTHER METRICS | |||||||||
| Accrued Preferred Stock Dividends | $3.3M | -- | $607.2K | -- | -- | -- | -- | ||
| Gain On Sale Of P P E | $191.7K | -- | -- | -- | -- | -- | -- | ||
| Net Operating Interest Income Expense | $298.2K | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $-348.2K | -- | $4.9M | $11.2M | $15.0M | $11.7M | $11.6M | ||
| Otherunder Preferred Stock Dividend | $3.3M | -- | $607.2K | -- | -- | -- | -- | ||
| Preferred Stock Dividends | $3.3M | -- | $607.2K | -- | -- | -- | -- | ||
| Rent And Landing Fees | $-348.2K | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | $6.5M | $4.9M | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NVNO | $0.80 | -8.1% | 2.08M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get enVVeno Medical Corporation Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW